Amelioration of heterophile antibody immunosensor interference

• US 8,828,738 B2
• Filed: 12/06/2011
• Issued: 09/09/2014
• Est. Priority Date: 03/25/2009
• Status: Active Grant

• Current Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Point Of Care Incorporated (Abbott Laboratories Incorporated)
• Inventors: Campbell, John Lewis Emerson, Omakor, John Emegbero
• Primary Examiner(s): Gabel, Gail R
• Application Number:
  US13/312,302
• Publication Number:
  US 20120073969A1
• Time in Patent Office: 1,008 Days
• Field of Search: 422/50, 422/61.8, 422/76, 422/82.01, 422/82.02, 422/82.03, 422/401, 422/417, 422/425, 422/503, 422/402, 435/7.1, 435/7.92, 435/7.94, 435/283.1, 435/286.5, 435/287.1, 435/287.2, 435/287.9, 435/288.5, 435/961, 436/512, 436/513, 436/514, 436/518, 436/540, 436/46, 436/166, 436/175, 436/177, 436/824, 436/825
• US Class Current: 436/513
• CPC Class Codes: G01N 2333/4712 Muscle proteins, e.g. myosin, actin, protein
• CPC Class Codes: G01N 2333/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
• CPC Class Codes: G01N 33/5306 Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
• CPC Class Codes: Y10S 436/824 Immunological separation techniques
• CPC Class Codes: Y10S 436/825 Pretreatment for removal of interfering factors from sample
• CPC Class Codes: Y10T 436/112499 with sample on test slide
• CPC Class Codes: Y10T 436/25125 Digestion or removing interfering materials
• CPC Class Codes: Y10T 436/25375 Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

The invention is directed to methods and devices for reducing interference from heterophile antibodies in an analyte immunoassay. In one embodiment, the invention is to a method comprising the steps of (a) amending a biological sample such as a whole blood sample with non-human IgM or fragments thereof by dissolving into said sample a dry reagent to yield a non-human IgM concentration of at least about 20 μg/mL or equivalent fragment concentration; and (b) performing an electrochemical immunoassay on the amended sample to determine the concentration of said analyte in said sample. Preferably, the sample is amended with IgG or fragments thereof in addition to the IgM of fragments thereof.

Claims

1. A device for performing an immunoassay of an analyte in a blood sample which is configured to reduce interference from heterophile antibodies, comprising a housing, an electrochemical immunosensor, a sample entry port, a conduit which permits a metered amount of blood sample to pass from the entry port to said immunosensor, and a dry reagent coated on at least one of said housing, said entry port, and said conduit comprising non-human IgM or fragments thereof in an amount sufficient to yield an IgM concentration of at least about 20 μ

g/mL or equivalent fragment concentration thereof in the metered blood sample in order to provide an amended sample having substantially sequestered heterophile antibodies therein.

2. The device of claim 1, wherein the dry reagent further comprises non-human IgG or fragments thereof.

3. The device of claim 2, further comprising a metering system for metering an initial blood sample to form the metered blood sample.

4. The device of claim 2, further comprising an immuno-reference sensor.

5. The device of claim 2, wherein the analyte is a cardiovascular marker.

6. The device of claim 2, wherein the immunoassay is for an analyte selected from the group consisting of, troponin I (TnI), troponin T (TnT), creatine kinase (CKMB), myoglobin, B-type natriuretic peptide (BNP), N-terminal pro b-type natriuretic peptide (NTproBNP), pro b-type natriuretic peptide (proBNP), beta-human chorionic gonadotrpoin (beta-HCG), thyroid-stimulating hormone (TSH), D-dimer, and prostate specific antigen (PSA).

7. The device of claim 2, wherein the sample is amended for a predetermined period by contacting the sample with the dry reagent for a time period in the range of from about 1 minute to about 30 minutes.

8. The device of claim 2, wherein the device is a single-use cartridge.

9. The device of claim 2, wherein the dry reagent further comprises an enzyme-labeled antibody to the analyte.

10. The device of claim 2, further comprising a second dry reagent coated on the device comprising an enzyme-labeled antibody to the analyte, wherein the second dry reagent is separate from the dry reagent that comprises the IgM or fragments thereof.

11. The device of claim 2, wherein the first dry reagent further comprises a component selected from the group consisting of buffer, salt, surfactant, stabilizing agent, a simple carbohydrate, a complex carbohydrate and combinations thereof.

12. The device of claim 2, wherein the non-human IgG or fragments thereof and non-human IgM or fragments thereof are murine, caprine or a combination thereof.

13. The device of claim 2, wherein the immunosensor performs an electrochemical enzyme-linked sandwich immunoassay.

14. The device of claim 2, wherein the immunosensor comprises an immobilized antibody to the analyte on an electrode.

15. The device of claim 2, wherein the analyte is TnI, and wherein said dry reagent dissolves into the metered blood sample to give an IgM concentration of from about 20 to about 200 μ

g/mL and an IgG concentration of from about 50 to about 5000 μ

g/mL.

16. The device of claim 2, wherein the analyte is TnI, and wherein said dry reagent dissolves into the metered blood sample to give an IgM concentration of from about 20 to about 60 μ

g/mL and an IgG concentration of from about 500 to about 1000 μ

g/mL.

17. The device of claim 2, wherein the analyte is BNP, and wherein said dry reagent dissolves into the metered blood sample to give an IgM concentration of from about 20 to about 200 μ

g/mL and an IgG concentration of from about 50 to about 5000 μ

g/mL.

18. The device of claim 2, wherein the analyte is BNP, and wherein said dry reagent dissolves into the metered blood sample to give an IgM concentration of from about 20 to about 60 μ

g/mL and an IgG concentration of from about 500 to about 1000 μ

g/mL.

19. The device of claim 2, further comprising a wash fluid contained in the device capable of washing said sample to a waste chamber.

20. The device of claim 2, further comprising a wash fluid comprising a substrate capable of reacting with an enzyme-labeled antibody bound to said immunosensor to form a product capable of electrochemical detection.

21. A device for performing an immunoassay of an analyte in a blood sample which is configured to reduce interference from heterophile antibodies, comprising a housing, an electrochemical immunosensor, a sample entry port, a conduit which permits a metered amount of blood sample to pass from the entry port to said immunosensor, and a dry reagent coated on at least one of said housing, said entry port, and said conduit comprising non-human IgM or fragments thereof and non-human IgG or fragments thereof at a weight ratio from 0.004 to 4 and in an amount sufficient to yield an IgM concentration of at least about 20 μ

g/mL or equivalent fragment concentration thereof in the metered blood sample in order to provide an amended sample having substantially sequestered heterophile antibodies therein.

22. The device of claim 21, wherein the weight ratio is from 0.02 to 2.

23. The device of claim 21, wherein the weight ratio is from 0.05 to 0.15.